Circulating Tumor DNA May Serve as a Prognostic Marker in Pancreatic Cancer

By Jo Cavallo
Posted: 12/20/2016 11:09:23 AM
Last Updated: 12/20/2016 11:09:23 AM
Tweet this page

Key Points

Plasma circulating tumor DNA (ctDNA) is an independent prognostic marker in patients with advanced pancreatic cancer and is associated with poorer overall survival.
Identifying ctDNA in blood samples using next-generation sequencing offers great potential as a noninvasive strategy for patient care and follow-up.
ctDNA is a promising blood biomarker, providing information about molecular abnormalities, and is associated with a prognostic and/or predictive value in other malignancies.